<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18194">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870036</url>
  </required_header>
  <id_info>
    <org_study_id>GV-LP-102</org_study_id>
    <nct_id>NCT02870036</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan and Simmitecan, 5-fluorouracil and Leucovorin Calcium, in Patients With Advanced Solid Tumors</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>ShangHai HaiHe Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Institute of Materia Medica, Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ShangHai HaiHe Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety, tolerability, preliminary efficacy and pharmacokinetics of
      Simmitecan in patients with advanced solid tumors and Simmitecan, 5-fluorouracil and
      Leucovorin Calcium in patients with advanced solid tumor or advanced/metastatic colorectal
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum plasma concentration)</measure>
    <time_frame>before administration (within 5 minutes before administration), 45 and 90 minutes after the start of the infusion of Simmitecan and at 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48 and 72 hours after the completion of infusion of Simmitecan</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (time to maximum plasma concentration)</measure>
    <time_frame>before administration (within 5 minutes before administration), 45 and 90 minutes after the start of the infusion of Simmitecan and at 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48 and 72 hours after the completion of infusion of Simmitecan</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (area under the plasma concentration-time curve)</measure>
    <time_frame>before administration (within 5 minutes before administration), 45 and 90 minutes after the start of the infusion of Simmitecan and at 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48 and 72 hours after the completion of infusion of Simmitecan</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T½</measure>
    <time_frame>before administration (within 5 minutes before administration), 45 and 90 minutes after the start of the infusion of Simmitecan and at 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48 and 72 hours after the completion of infusion of Simmitecan</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL (systemic clearance)</measure>
    <time_frame>before administration (within 5 minutes before administration), 45 and 90 minutes after the start of the infusion of Simmitecan and at 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48 and 72 hours after the completion of infusion of Simmitecan</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz (apparent volume of distribution)</measure>
    <time_frame>before administration (within 5 minutes before administration), 45 and 90 minutes after the start of the infusion of Simmitecan and at 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48 and 72 hours after the completion of infusion of Simmitecan</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>AEs will be classified by type, incidence, severity (graded per NCI-CTCAE [version 4.03]), time to onset, seriousness and relationship</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Imaging examination will be performed for tumor assessment every 6 weeks (±7 days) from the first dose of Simmitecan until PD, intolerable toxicity, withdrawal of consent or death.</time_frame>
    <description>Tumor will be evaluated according to RECIST-1.1. CT or MRI can be used for tumor imaging at the investigator's discretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>Imaging examination will be performed for tumor assessment every 6 weeks (±7 days) from the first dose of Simmitecan until PD, intolerable toxicity, withdrawal of consent or death.</time_frame>
    <description>Tumor will be evaluated according to RECIST-1.1. CT or MRI can be used for tumor imaging at the investigator's discretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBR (clinical benefit rate)</measure>
    <time_frame>Imaging examination will be performed for tumor assessment every 6 weeks (±7 days) from the first dose of Simmitecan until PD, intolerable toxicity, withdrawal of consent or death.</time_frame>
    <description>Tumor will be evaluated according to RECIST-1.1. CT or MRI can be used for tumor imaging at the investigator's discretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR (disease control rate)</measure>
    <time_frame>Imaging examination will be performed for tumor assessment every 6 weeks (±7 days) from the first dose of Simmitecan until PD, intolerable toxicity, withdrawal of consent or death.</time_frame>
    <description>Tumor will be evaluated according to RECIST-1.1. CT or MRI can be used for tumor imaging at the investigator's discretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (overall survival)</measure>
    <time_frame>Imaging examination will be performed for tumor assessment every 6 weeks (±7 days) from the first dose of Simmitecan until PD, intolerable toxicity, withdrawal of consent or death.</time_frame>
    <description>Tumor will be evaluated according to RECIST-1.1. CT or MRI can be used for tumor imaging at the investigator's discretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>accumulative excretion rate</measure>
    <time_frame>Accumulative excretion rate within 0-72 h after the first administration of Simmitecan.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Advanced/Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetic data investigation of Simmitecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To further determine the pharmacokinetic (PK) characteristics of Simmitecan monotherapy in patients with advanced solid tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation study of Simmitecan combined therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the maximum tolerated dose (MTD) of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced solid tumor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose extension study of Simmitecan monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To preliminarily evaluate the anti-tumor activity of Simmitecan monotherapy in patients with advanced solid tumors, and to determine the recommended phase II dose (RP2D)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose extension study of Simmitecan combined therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To preliminarily evaluate the anti-tumor activity of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced/metastatic colorectal cancer (CRC), and to determine RP2D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simmitecan</intervention_name>
    <arm_group_label>Pharmacokinetic data investigation of Simmitecan</arm_group_label>
    <arm_group_label>Dose escalation study of Simmitecan combined therapy</arm_group_label>
    <arm_group_label>Dose extension study of Simmitecan monotherapy</arm_group_label>
    <arm_group_label>Dose extension study of Simmitecan combined therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil and Leucovorin Calcium</intervention_name>
    <arm_group_label>Dose escalation study of Simmitecan combined therapy</arm_group_label>
    <arm_group_label>Dose extension study of Simmitecan combined therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. To be enrolled in the study, all patients shall meet all the following criteria:
             Patients who have fully understood the study, and are willing to sign the informed
             consent form(ICF);

          2. To be enrolled in part 1, 2 and 3 of the study, patients should be diagnosed as
             advanced solid tumor by pathological histology and/or cytology; and patients should
             be diagnosed as advanced or metastatic CRC by pathological histology prior to
             enrollment in part 4 of the study; Note: the patients enrolled in the part 2 of the
             study shall be patients with advanced solid tumor who is suitable for the regimen of
             Simmitecan combined with 5-FU-LV as judged by the investigator;

          3. Patients who had failed standard treatments for advanced cancer, or are intolerant to
             the current standard treatments, or have no suitable standard treatments for advanced
             cancer;

          4. Patients who have at least one measurable lesion (according to RECIST, version 1.1);
             note: the lesions previously treated with radiotherapy cannot be regarded as the
             target lesion, unless the lesion showed definite progression after radiotherapy;

          5. Patients with Eastern Cooperative Oncology Group (ECOG) performance status score of 0
             or 1;

          6. Patients aged ≥ 18 years and ≤ 70 years, male or female is allowed;

          7. Patients with life expectancy of 12 weeks or more;

          8. Patients with appropriate organ function as documented by:

               1. Absolute neutrophil count ≥ 1.5×109/L;

               2. Hemoglobin ≥ 9 g/dL (without erythrocyte transfusions within 14 days);

               3. Platelet count ≥ 100×109/L.

               4. Total serum bilirubin ≤ 1.5 times of upper limit of normal (ULN) (for the
                  patients with Gilbert syndrome, total bilirubin is allowed to be ≤ 3×ULN and
                  direct bilirubin is allowed to be 1.5×ULN);

               5. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5×ULN, or
                  AST and ALT ≤ 5×ULN for patients with liver metastasis;

               6. Creatinine clearance ≥ 50 mL/min ;

               7. International normalized ratio (INR) ≤ 1.5 × ULN, or activated partial
                  thromboplastin time (aPTT) ≤ 1.5 × ULN (INR only for patients who have not
                  received anticoagulant therapy).

          9. Patients with negative hepatitis b surface antigen; for patients with positive
             hepatitis b surface antigen, quantitative result of hepatitis b virus (HBV) DNA
             should be &lt; 1000 cps/mL;

         10. Toxicity caused by any previous treatment, surgery or radiotherapy have recovered to
             CTCAE grade 0 or 1 (except for alopecia );

         11. Female patients are eligible for the study if the following conditions are met:

               1. Patients have no fertility (i.e., physiological infertility), including
                  postmenopausal period (complete menolipsis for more than 1 year) or documented
                  irreversible sterilization operation including hysterectomy, bilateral
                  ovariectomy, or bilateral salpingectomy (instead of tubal ligation);

               2. For patients of childbearing potential, the results of serum pregnancy test
                  screening should be negative (within 7 days before the first dose of
                  investigational drug), and breastfeeding is not allowed before the start of the
                  study and throughout the study. Moreover, the patients should agree to take
                  effective contraception measures during the study and within 90 days after the
                  last dose, and should always conduct strict birth control in accordance with the
                  label of drug/appliance and the investigator's instructions. Effective
                  contraception measure is defined as:

                    -  The sexual partner with removed deferens is the only sexual partner of
                       female patient;

                    -  Use of any intrauterine device with documented failure rate less than 1%
                       per year;

                    -  Double contraception, such as spermicide plus male condom, female condom,
                       diaphragm, cervical cap or intrauterine contraceptive device.

         12. Male patients should have undergone vasectomy, or agree to take effective
             contraception measures during the study and within 90 days after the last dose;

         13. Patients are able to follow the study procedures, restrictions and requirements at
             the investigator's discretion.

        Exclusion Criteria:

          -  1. Patients are still within 5 half-life of previous anticancer chemotherapy,
             biological agents or other investigational drugs (if 5 half-life exceeds 28 days
             calculated as 28 days) at the time of screening;

             2. Patients received systemic radiotherapy (including whole brain radiotherapy)
             within 28 days before enrollment, or received small area radiotherapy (stereotactic
             radiotherapy of central nervous system (CNS)) within 7 days before enrollment, or
             have not yet recovered from the previous radiotherapy;

             3. Patients have not yet recovered from the toxic reaction (except alopecia ) caused
             by previous anti-tumor treatments (&gt; CTCAE grade 2);

             4. Patients underwent major surgery or have not yet fully recovered from pervious
             surgery (major surgery is defined as grade 3 or 4 surgery specified in &quot;Management
             Measures for Clinical Application of Medical Technology&quot; implemented on May 1st,
             2009).

             5. Patients had CNS metastasis or cancer-related epilepsy requiring clinical
             intervention; however, patients with CNS metastasis who received treatments, or the
             asymptomatic patient can be enrolled;

             6. Patients with a history of allergy to 5-FU or LV;

             7. Patients with active HBV or hepatitis C virus (HCV) infection;

             8. Patients diagnosed with human immunodeficiency virus (HIV) infection, or are not
             willing to have HIV test;

             9. Patients with clinically significant active infection;

             10. Patients with previous or concurrent other malignant tumors (except effectively
             controlled non-melanoma skin basal cell carcinoma, breast/cervical carcinoma in situ,
             or other effectively controlled tumors in the past 5 years even without treatments);

             11. Patients with impaired cardiac function or clinically significant heart diseases,
             including grade 2 or higher congestive heart failure per New York Heart Association
             (NYHA) classification, arrhythmia, conduction abnormalities requiring treatment,
             cardiomyopathy, or uncontrolled hypertension;

             12. Patients with serious kidney damage requiring kidney dialysis;

             13. Patients with serious liver damage, grade B or C end-stage liver diseases per
             Child-Pugh classification (see appendix 8);

             14. Any other diseases or conditions with clinical significance that may affect the
             protocol compliance or patient's signature of ICF at the investigator's discretion
             (such as uncontrolled diabetes, etc.);

             15. Patients with disease of digestive tract such as duodenal ulcer, ulcerative
             colitis, intestinal obstruction or other conditions that may cause alimentary tract
             hemorrhage or gastrointestinal perforation as judged by the investigator, or have
             past medical history of gastric-intestinal perforation or intestinal fistula;

             16. Patients with physical condition that will cause the risk of investigational drug
             use, or render the toxicity or adverse effect difficult to explain at the
             investigator's discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijin</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, M.D.</last_name>
      <phone>8610-88196561</phone>
      <email>lin100@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Lin Shen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>50011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Da Jiang, M.D.</last_name>
      <phone>13933191980</phone>
      <email>jiangda139@163.com</email>
    </contact>
    <investigator>
      <last_name>Da Jiang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianglin Yuan, M.D.</last_name>
      <phone>8627-83662299</phone>
      <email>yxl@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Xianglin Yuan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nong Yang, M.D.</last_name>
      <phone>13055193557</phone>
      <email>yangnong0217@163.com</email>
    </contact>
    <investigator>
      <last_name>Nong Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yunpeng Liu, M.D.</last_name>
      <phone>13898865122</phone>
      <email>cmu_trial@163.com</email>
    </contact>
    <investigator>
      <last_name>Yunpeng Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junning Cao, M.D.</last_name>
      <phone>13651680209</phone>
      <email>cao_junning@126.com</email>
    </contact>
    <investigator>
      <last_name>Junning Cao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Ba, M.D.</last_name>
      <phone>13752157916</phone>
      <email>bayi@tjmuch.com</email>
    </contact>
    <investigator>
      <last_name>Yi Ba, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, André T, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Boucher E, Rebischung C, Hammel P, Rougier P, Bedenne L, Bouché O. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014 Nov 1;32(31):3520-6. doi: 10.1200/JCO.2013.54.1011. Epub 2014 Oct 6. Erratum in: J Clin Oncol. 2015 Apr 20;33(12):1416.</citation>
    <PMID>25287828</PMID>
  </reference>
  <results_reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338.</citation>
    <PMID>26808342</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>August 3, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
